“I take a contrarian position to views that the Internal DEP is a big flop ….” ~ @Wingmann
Literally no one on this forum has said this. So please do not put words in anyone’s mouth or infer it is the view of others on here.
What I have said, is that it’s still my opinion, and looking more likely with every subsequent update, that DEP-Docetaxel will be a dud.
Late 2018, early 2019 is when CEO Jackie Fairley said the DEP-Docetaxel Phase 2 trial would be completed.
So after 3 months of no new recruited patients, Starpharma is now commencing screening of new patients for god knows what arm of mono therapy or combination.
If only there was a way to keep shareholders fully informed. Perhaps something like a report to shareholders via the ASX 4 times a year. Like a quarterly report.
PATIENCE, page-36
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.7¢ |
Change
-0.003(3.00%) |
Mkt cap ! $42.78M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 9.7¢ | $111.3K | 1.115M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 43696 | 9.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 130967 | 1 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| SPL (ASX) Chart |